A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
0.50 hr(s) | ABIM , CME , MOC , Royal College of Physicians and Surgeons of Canada
Therapeutic Area(s): Oncology
Release Date: August 25, 2021
Expiration Date: August 24, 2022
Location: Internet Activity Enduring
In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis.